Light treatment equipment for treating Alzheimer's disease and related diseases thereof

Abstract

The invention relates to light treatment equipment for treating Alzheimer's disease and related diseases. The light treatment equipment comprises a bearing mechanism and an array of near-infrared irradiation units. The apparatus emits near-infrared light into the accommodation space, the irradiation of the emitted near-infrared light to the subject head in the event that the subject head is in place satisfies a synergistic irradiation condition of an irradiation surface area ratio and an irradiation power level with respect to a reference head cover surface area, the surface area of the reference head cover part is the outer surface area of the surface of the head of the object in a total boundary line, the total boundary line passes through anterior auricular points on two sides along the eyebrow bone from an interbrow point, backwards surrounds and passes through electrode positions O1, OZ and O2 of an occipital bone protrusion and a 10-10 international standard lead system to be converged, and the proportion of the irradiation surface area can be as low as 30%; and the yield can be up to 65% or above. The equipment can realize robust and continuous remarkable curative effects on AD and related diseases of a treated object.

Description

A light therapy device for treating Alzheimer's disease and related diseases Technical Field The present application belongs to the technical field of light therapy equipment for brain and cognitive diseases, and in particular, to a light therapy equipment for treating Alzheimer's disease and its related diseases. Background Art Alzheimer's disease (AD) is a chronic, progressive neurodegenerative disease that primarily affects the elderly, especially those over 60 years old. The disease is characterized by memory loss, loss of social and occupational function, executive dysfunction, speech and motor deficits, personality changes, and behavioral and psychological disorders. The course of the disease can last up to 8-10 years, and there is currently no cure, placing a heavy burden on families and society. At present, the pathogenesis of AD is not fully understood, but the generally accepted mechanism is: abnormal processing of amyloid precursor protein (APP) produces β-amyloid protein (Aβ), which aggregates to form amyloid plaques; abnormal phosphorylation of Tau protein forms neurofibrillary tangles (NFTs), and the accumulation of these tangles in the brain leads to damage and dysfunction of nerve cells; further, intracellular NTFs and extracellular Aβ deposition form senile plaques, resulting in increased oxidative stress, increased neuroinflammation and mitochondrial dysfunction, which in turn causes neuronal dysfunction and synaptic loss, ultimately leading to neuronal death. Long-term clinical practice has shown that the use of drugs, such as cholinesterase inhibitors, memantine, and the recently emerged lencanezumab (a humanized monoclonal antibody that can reduce the deposition of beta-amyloid protein in the brain), combined with conventional treatment, can usually only improve mild cognitive impairment (MCI) or mild AD, and there is also the problem of frequent gastrointestinal adverse reactions. In recent years, photobiomodulation (PBM) has been introduced to treat AD. PBM applies red light or near-infrared light with a wavelength range of 600 to 1100nm to the head, which passes through the scalp and skull to act on brain tissue. It treats AD non-invasively through multiple mechanisms, such as increasing Aβ clearance, reducing abnormal aggregation of Tau protein, improving metabolism and mitochondrial function, increasing cerebral blood flow, and improving anti-oxidative stress and anti-inflammatory capabilities. However, the irradiation parameters of various existing photobiomodulation devices (also referred to as light therapy devices in this article) are vague, confusing and vary widely. For example, although the optical power density of near-infrared light (unit: mW / cm 2) as the irradiation parameter, but the action position of the light power density is sometimes close to the exit surface of the LED (see Farzad Salehpour et al., Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report, Photobiomodul Photomed Laser Surg. 2019Mar; 37(3): 159-167), sometimes a few centimeters inward from the inner wall of the head cap (see Liang Chen et al., A Pilot Study of Near-Infrared Light Treatment for Alzheimer's Disease, Journal of Alzheimer's Disease 91(2023)191–201), and sometimes the depth under the dura mater (see US8308784B2). Just in terms of the LED's close exit surface, for photobiomodulation devices with different structures, even if the surface has the same light power density, the actual dose acting on the intracranial tissue will have significant differences. As shown in Figure 1(a), the LED light board is set in the housing of the head cap, with a predetermined distance from the subject's head and a gap that causes light attenuation at this distance; as shown in Figure 2(a), several LED light boards are combined into an irradiation unit, and the irradiation unit is close to the subject's head; as shown in Figure 2(b), the LED light board is suspended at a large distance around the subject's head in the air. Obviously, in these three light therapy devices, even if the adjacent exit surface of each LED has the same light power density, the dose penetrating the scalp and skull to act on the brain tissue is very different. In addition, the irradiation parameters defined at the location in the body are not practical for irradiation control of phototherapy equipment. For example, the light power density at a depth of several centimeters below the dura mater mentioned above is not possible to operate the light every time. Treatment equipment must invasively measure the optical power density deep in the brain - several centimeters below the dura mater. At present, manufacturers and researchers of near-infrared light therapy equipment usually simply measure and list the light power density at different locations used as mentioned above. The light power density used also varies greatly. For example, US9993659B2 records that the light power density at the light emitting surface is about 1400mW / cm 2 About 4200mW / cm 2, while Farzad Salehpour et al., Rapid Reversal of Cognitive Decline, Olfactory Dysfunction, and Quality of Life Using Multi-Modality Photobiomodulation Therapy: Case Report, Photobiomodul Photomed Laser Surg. 2019 Mar; 37(3): 159-167, recorded a light power density of 31 mW / cm at the light emitting surface. 2 The light power density of the two is 40-140 times different, but both claim to have a therapeutic effect on AD. It is confusing as to what level of light power density should be used at what position to have a good therapeutic effect on AD. Does limiting the light power density at a certain position necessarily have a good therapeutic effect on AD? Although manufacturers and researchers of near-infrared light therapy equipment will list the power (in W) at various positions (such as the light-emitting surface of the LED), it is not clear what the relationship between power and the AD therapeutic effect on the subject is. Specifically, some of the power they use is the luminous power of the lamp panel, and some is the luminous power at the brain tissue. It is not clear whether the duty cycle is converted (is it the time-averaged luminous power or the peak luminous power), and the orders of magnitude are very different. Furthermore, it is clearly recorded in US8308784B2 that "for the selected wavelength, the power density (light intensity or power per unit area, W / cm 2 ) or energy density (energy per unit area, in J / cm 2 The amount of light energy delivered to tissue (power density multiplied by exposure time) is an important factor in determining the relative efficacy of phototherapy, while efficacy has no direct relationship with the total power or total energy delivered to tissue (see its instructions,

[0192] Is it true that the efficacy of a near infrared light therapy device for treating AD in a subject has no direct relationship to the total power or energy delivered to the tissue? In summary, the existing technology has different opinions on the dosage required for near-infrared light therapy equipment, and even contradicts each other, which hinders the promotion and development of near-infrared light therapy equipment and even near-infrared light therapy methods. Summary of the invention This application is proposed to solve the above problems existing in the prior art. This application aims to provide a light therapy device for treating Alzheimer's disease and its related diseases, which is not limited to a specific structure, nor is it limited to whether the near-infrared irradiation unit is an ordinary LED or a low-energy laser diode. As long as the unified coordinated irradiation conditions are met, it can achieve a robust and sustained significant therapeutic effect on AD and its related diseases of the treated subject. According to the first scheme, the present application provides a phototherapy device for treating Alzheimer's disease and its associated diseases, the phototherapy device comprising a carrying mechanism and an array of near-infrared irradiation units. The carrying mechanism is configured to form a storage space for the subject's head and to carry an array of near-infrared irradiation units. The array of near-infrared irradiation units is configured to emit near-infrared light into the storage space, and when the subject's head is in place in the storage space, the irradiation of the subject's head by the emitted near-infrared light satisfies the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level. Wherein, the irradiation surface area ratio is the ratio of the irradiation surface area to the reference skull cover surface area, and the reference skull cover surface area is the outer surface area of ​​the surface of the subject's head within the total boundary line. Furthermore, the total boundary line runs from the glabella of the subject's head along the brow bone through the preauricular points on both sides, and then goes back around the occipital protuberance and merges between the electrode positions O1, OZ and O2 of the 10-10 international standard lead system. The irradiated surface area ratio can be as low as 30% (which can be called a local concentrated stimulation scheme) or as high as 65% or more (which can be called a multi-zone balanced stimulation scheme). In the present application, the term "irradiation to the head of the subject" is intended to mean irradiation to the outer thin irradiation surface of the head of the subject that contacts the hair (or scalp if there is no hair). Energy irradiation to the outer thin irradiation surface means that the energy is transferred to the head including the hair, scalp, skull and brain tissue. Furthermore, the transferred energy can act on the cortex or even deeper in the brain tissue after being absorbed by the hair and attenuated by the scalp and skull. The energy at the location is related to the attenuation on the transmission path. In this application, the so-called "time-averaged optical power density" is intended to mean the optical power density averaged over time. For example, the "time-averaged optical power density" of a target site is intended to mean the optical power density averaged over time at the target site. For another example, the "time-averaged optical power density" of a target portion is intended to mean the "time-averaged optical power density" of a representative position on the target portion. Specifically, the "time-averaged optical power density" of the target portion is 30-60 mW / cm 2 , which means that the time-averaged optical power density at each representative position on the target part, such as but not limited to the corresponding position of the center of the light board, is 30-60mW / cm 2 fluctuates within the range of The so-called "temporal and spatial average optical power density" to the target area is intended to mean the time-averaged optical power density averaged relative to the surface area of ​​the target area, that is, the optical power density after averaging operations are performed relative to both the surface area and time. As long as the irradiation of the emitted near-infrared light to the head of the subject meets the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level, for example but not as a limitation, for black thick hair wearing a light guide comb as described in the patent application number PCT / CN2021 / 126700 of the present applicant, or for light-colored thick hair without a light guide comb, or for black sparse hair wearing or not wearing the light guide comb, near-infrared light of sufficient optical power can be delivered to sufficient areas of brain tissue per unit time. The irradiation surface area ratio of the local concentrated stimulation scheme can be as low as 30%, and as high as 65% or more to constitute a multi-zone balanced stimulation scheme. The irradiation power level that matches the irradiation surface area ratio within this range can achieve "modulation" and "excitation" of a sufficient proportion of cell populations. After a sufficient proportion of cell populations are "modulated" and "excited", not only will they themselves undergo a change response that inhibits AD, but they can also transmit and diffuse the change response to other cell populations on the AD development spatial trajectory, thereby achieving a comprehensive AD inhibition effect throughout the brain. In this way, not only can the Aβ plaques accumulated in the neocortex be significantly reduced, the abnormal aggregation of tau protein in the neocortex, hippocampus and even limbic cortex be significantly reduced, but also the AD-specific lesions of cell populations throughout the brain can be inhibited and eliminated, thereby effectively inhibiting the progression of AD. In some embodiments, adapted coordinated irradiation conditions may be provided for local concentrated stimulation schemes and multi-zone balanced stimulation schemes. Specifically, the irradiated surface area ratio of the local concentrated stimulation scheme is smaller than that of the multi-zone balanced stimulation scheme, and the matched irradiation power level is also higher than that of the multi-zone balanced stimulation scheme. For example, as a local concentrated stimulation scheme, when the irradiated surface area ratio is 30% to 40%, the time-space average optical power density is required to be 117mW / cm 2 When the irradiated surface area ratio is between 40% and 65%, the spatiotemporal average optical power density irradiated to the subject's head is 110 mW / cm 2 In this way, it is possible to break through the limitations of local cell populations, fully "modulate" and "stimulate" cell populations, and transmit and spread the response of inhibiting AD changes to other cell populations in a wider area on the spatial trajectory of AD development. The multi-zone balanced stimulation scheme requires an average synergistic dose of 2750W*% to 14100W*%, which is the product of the percentage of the irradiated surface area ratio and the average total power, so the unit is watt*percentage. For example, if the irradiated surface area ratio is 65%, then its percentage is 65, and the average synergistic dose is the average total power multiplied by 65W*%. As the affected cell populations are more widely distributed, such as in multiple brain regions, multiple brain functional networks, etc., by delivering the above average synergistic dose, the cell population can be appropriately "modulated" and "excited", and the response to inhibiting AD changes can be transmitted and diffused to other cell populations in a wide area on the spatial trajectory of AD development. Compared with the prior art, the beneficial effects of the embodiments of the present application are as follows. The light therapy device is not limited to a specific structure, nor is it limited to whether the near-infrared irradiation unit is an ordinary LED or a low-energy laser diode. It ensures that the irradiation of the near-infrared light to the head of the object satisfies the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level, that is, a sufficient composite dose of the time-averaged irradiation power and the irradiation surface area ratio is delivered to the head of the object, thereby embedding the group response characteristics of cell subpopulations and the action mechanism of brain functional networks, as well as the whole-brain progression characteristics of AD. By irradiating a sufficient composite dose of near-infrared light to the head of the object, whether it is a local concentrated stimulation scheme or a multi-zone balanced stimulation scheme, it is possible to achieve a sufficient proportion of cell populations. "Modulation" and "excitation". After a sufficient proportion of cell populations are "modulated" and "excited", not only will they themselves undergo a change response that inhibits AD, but they will also be able to transmit and diffuse the change response to other cell populations on the AD development spatial trajectory, thereby achieving a comprehensive AD inhibition effect throughout the brain. In this way, not only can the Aβ plaques accumulated in the neocortex be significantly reduced, the abnormal aggregation of tau protein in the neocortex, hippocampus and even limbic cortex be significantly reduced, but also the AD-specific lesions of cell populations throughout the brain can be inhibited and eliminated, thereby effectively inhibiting the progression of the AD course. The inhibitory effect of the phototherapy device of the present application on the course of AD has also been confirmed in clinical experiments. Not only did the cognitive level of the subjects significantly improve during the period of phototherapy, but also during the period after the cessation of phototherapy, a series of biochemical reactions caused by light radiation continued to trigger an inhibitory effect, not only maintaining the inhibitory effect on AD to a certain extent, but even continuing to promote the inhibitory effect on AD, and the cognitive level was still maintained or improved without deterioration callback (described in detail below). It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention. This summary of various implementations or examples of the technology described in this disclosure is not a comprehensive disclosure of the entire scope or all features of the disclosed technology. BRIEF DESCRIPTION OF THE DRAWINGS In the drawings, which are not necessarily drawn to scale, the same reference numerals may describe similar parts in different views. The same reference numerals with letter suffixes or different letter suffixes may represent different instances of similar parts. The accompanying drawings generally illustrate various embodiments by way of example and not limitation, and together with the specification and claims, are used to illustrate the embodiments of the invention. When appropriate, the same reference numerals are used throughout the drawings to refer to the same or similar parts. Such embodiments are illustrative and are not intended to be exhaustive or exclusive embodiments of the present apparatus or method. FIG. 1( a ) shows a schematic diagram of a light therapy device according to a first embodiment of the present application; FIG1( b ) shows a schematic structural diagram of a head-mounted device of a light therapy device according to a first embodiment of the present application. FIG. 2( a ) shows a schematic diagram of a light therapy device according to a second embodiment of the present application; FIG. 2( b ) shows a schematic diagram of a light therapy device according to a third embodiment of the present application. 3( a ) to 3 ( f ) are schematic diagrams of reference head models of a treatment group according to an embodiment of the present application. Figure 4(a) shows a front view of a reference head model according to the fourth embodiment of the present application, which serves as an example of an object head. The electrode positions of the 10-10 international standard lead system, the overall boundary line of the reference skull cap, and the boundary lines between the front upper part of the skull, the left side of the skull, and the right side of the skull are shown on the object head. Figure 4(b) shows a left side view of a reference head model according to the fourth embodiment of the present application, which serves as an example of an object head. The electrode positions of the 10-10 international standard lead system, the overall boundary line of the reference skull cap, and the boundary lines between the front upper part of the skull, the left side of the skull, the top of the skull, and the back of the skull are shown on the object's head. Figure 4(c) shows a right side view of a reference head model according to the fourth embodiment of the present application, which serves as an example of an object head. The electrode positions of the 10-10 international standard lead system, the overall boundary line of the reference skull cap, and the boundary lines between the front upper part of the skull, the right side of the skull, the top of the skull, and the back of the skull are shown on the object's head. Figure 4(d) shows a top view of a reference head model according to the fourth embodiment of the present application, which serves as an example of an object head. The electrode positions of the 10-10 international standard lead system, the overall boundary line of the reference skull, and the boundary lines between the front upper part of the skull, the top of the skull, the left side of the skull, the right side of the skull, and the back of the skull are shown on the object's head. Figure 4(e) shows a rear view of a reference head model according to the fourth embodiment of the present application, which serves as an example of an object head. The electrode positions of the 10-10 international standard lead system, the overall boundary line of the reference skull cap, and the boundary lines between the top of the skull, the left side of the skull, the right side of the skull, and the back of the skull are shown on the object's head. FIG. 5( a ) is a schematic diagram showing the upper front part of the skull of a reference head model as an example of a subject's head according to the fifth embodiment of the present application. FIG5(b) shows a schematic diagram of the upper front part of the skull of a reference head model as an example of a subject's head according to the sixth embodiment of the present application. FIG5(c) is a schematic diagram showing the upper front part of the skull of a reference head model as an example of a subject's head according to the seventh embodiment of the present application. FIG. 6( a ) shows an exemplary diagram of an irradiation area according to an eighth embodiment of the present application. FIG6( b ) shows an exemplary diagram of an irradiation area according to a ninth embodiment of the present application. FIG6( c ) shows an exemplary diagram of an irradiation area according to the tenth embodiment of the present application. FIG6( d ) shows an exemplary diagram of an irradiation area according to the eleventh embodiment of the present application. FIG. 7 shows a bottom view of a head cap of a light therapy device according to a twelfth embodiment of the present application. FIG8 is a schematic diagram showing an arrangement structure of a light board according to a thirteenth embodiment of the present invention. FIG. 9 is a schematic diagram showing the arrangement structure of a lamp panel frame according to a fourteenth embodiment of the present invention. FIG. 10 is a schematic diagram showing a process of conducting a clinical experiment on AD patients using a light therapy device according to an embodiment of the present application. FIG11( a ) shows a graph showing changes in the ADAS-Cog scale scores of the control group before near-infrared light therapy, during near-infrared light therapy, and after cessation of near-infrared light therapy. FIG11( b ) shows a graph showing changes in the ADAS-Cog scale scores of the experimental group before near-infrared light therapy, during near-infrared light therapy, and after cessation of near-infrared light therapy. FIG12( a ) shows a graph showing changes in the MMSE scale scores of the control group before near-infrared light therapy, during near-infrared light therapy, and after cessation of near-infrared light therapy. FIG12( b ) shows a graph showing changes in the MMSE scale scores of the experimental group before near-infrared light therapy, during near-infrared light therapy, and after cessation of near-infrared light therapy. DETAILED DESCRIPTION In order to make the purpose, technical solution and advantages of the embodiment of the present invention clearer, the technical solution of the embodiment of the present invention will be clearly and completely described below in conjunction with the drawings of the embodiment of the present invention. Obviously, the described embodiment is a part of the embodiment of the present invention, not all of the embodiments. Based on the described embodiment of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention. Unless otherwise defined, the technical terms or scientific terms used in the present invention should be understood by people with ordinary skills in the field to which the present invention belongs. The words "first", "second" and similar words used in the present invention do not indicate any order, quantity or importance, but are only used to distinguish different components. "Include" or "comprise" and similar words mean that the elements or objects appearing before the word include the elements or objects listed after the word and their equivalents, without excluding other elements or objects. "Connect" or "connected" and similar words are not limited to physical or mechanical connections, but may include electrical connections, whether direct or indirect. "Up", "down", "left", "right" and the like are only used to indicate relative positional relationships. When the absolute position of the described object changes, the relative positional relationship may also change accordingly. In order to keep the following description of the embodiments of the present invention clear and concise, detailed descriptions of well-known functions and well-known components are omitted. The present application aims to provide a light therapy device for treating Alzheimer's disease and its associated diseases. The expression "used to treat Alzheimer's disease and its associated diseases" in the present application is intended to indicate that the progression of Alzheimer's disease and its associated diseases is alleviated, inhibited, terminated or even reversed. The so-called associated diseases of Alzheimer's disease are intended to indicate that the subject has not yet shown obvious clinical symptoms of AD, but has some pathological or physiological phenomena associated with AD and will develop into AD with a certain probability. The so-called Alzheimer's disease and The course of its associated diseases is intended to include the clinical symptoms of AD that the subject has already developed and the subsequent development process, and also includes the process in which the subject has not yet clearly developed clinical symptoms of AD, but there are some pathological or physiological phenomena associated with AD and that will develop into AD with a certain probability. That is to say, the expression "for the treatment of Alzheimer's disease and its associated diseases" in this application includes the treatment of Alzheimer's disease of various courses (from MCI to severe dementia), and also includes the treatment of other diseases associated with Alzheimer's disease. Specifically, according to the 2018 AD diagnostic criteria of the National Institute on Aging and the Alzheimer's Association (NIA-AA), based on the β-amyloid protein (Aβ) and tau in the brain or cerebrospinal fluid of the population, as well as the examination results of cranial MRI and FDG-PET, biomarkers can be divided into 4 categories, and cognitive functions can be further divided into 6 levels. Level 1 is characterized by normal objective cognitive neuropsychological tests, no cognitive complaints, no neurobehavioral symptoms, no informed reports of cognitive decline or neurobehavioral symptoms, and no follow-up test evidence of cognitive decline; Level 2 includes subjective cognitive decline (SCD), objective mild cognitive decline (Obj-SCD), and neurobehavioral symptoms; Levels 1 and 2 are collectively referred to as the preclinical stage. Level 3 is abnormal or impaired objective cognitive tests, but has not reached dementia, that is, MCI. Levels 4-6 are mild, moderate, and severe dementia, respectively. At each of these 6 levels, if there is a positive test result for a biomarker, it can belong to the course of Alzheimer's disease defined in this application. Furthermore, for subjects who carry genes associated with the risk of AD but whose current test results are Aβ negative, such as APOEε4, ABCA7, CLU, CR1, PICALM, PLD3 and TREM2, even if their cognitive function is at level 1, medical intervention to reduce their risk of developing AD or slow down the process of developing AD can also be regarded as "associated conditions for the treatment of Alzheimer's disease" in this application. The phototherapy device includes a carrying mechanism 101 and an array 102 of near-infrared irradiation units. The carrying mechanism 101 is configured to form a storage space for the subject's head 103 and to carry the array 102 of near-infrared irradiation units. The array 102 of near-infrared irradiation units is configured to emit near-infrared light into the storage space. The carrying mechanism 101 and the array 102 of near-infrared irradiation units can adopt various structures as needed, for example, see Figures 1(a), 2(a) and 2(b), which will be described in detail below, but the structure of the phototherapy device is not limited thereto. When the subject's head 103 is in place in the accommodation space, the irradiation of the emitted near-infrared light to the subject's head satisfies the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level. The irradiation surface area ratio is the ratio of the irradiation surface area to the surface area of ​​the reference head cover 401. The so-called "in place" in this application is intended to indicate that the subject's head 103 is in the desired treatment position in the phototherapy device, that is, it has the desired spatial position and spatial orientation. Usually, when the subject's head 103 is "in place", the phototherapy device can be turned on. For example, when in place, the center of gravity of the subject's head 103 can be aligned with the center of the accommodation space, and the central axes in the front-to-back direction are aligned with each other. For another example, when in place, the subject's head 103 can be centered in the accommodation space, with the front-to-back distance from the front and rear walls of the accommodation space being substantially consistent, and the left-right distance from the left and right walls of the accommodation space being substantially consistent. For another example, taking the phototherapy head cap shown in FIG1( a) as an example, when in place, the brow bone of the subject's head 103 can be aligned with the front edge of the head cap, and the subject's head 103 is located in the center of the head cap, so that the front and rear sides are substantially the same distance from the irradiated surface of the inner shell, and the left and right sides are substantially the same distance from the irradiated surface of the inner shell. The surface area of ​​the reference skull is the outer surface area of ​​the head of the subject within the total boundary line 400, which runs from the eyebrow point of the subject's head along the brow bone through the preauricular points on both sides, and then goes back around the occipital protuberance and merges between the electrode positions O1, OZ and O2 of the 10-10 international standard lead system, as shown in Figures 4(a), 4(b), 4(c) and 4(e). The irradiated surface area ratio can be as low as 30% (which can be called a local concentrated stimulation scheme) or as high as 65% or more (which can be called a multi-zone balanced stimulation scheme). The inventors have creatively discovered through clinical experiments, including individual experiments and experiments on a certain range of target populations, that the effect of treating Alzheimer's disease and its related diseases by irradiating near-infrared light of the same wavelength cannot be determined solely by the light power density. The irradiation power level that can be transmitted to the brain tissue and the irradiation surface area ratio are both important factors, and the effect is determined in a synergistic manner. Furthermore, the energy attenuation of near-infrared light passing through the skull can be measured. For example, see Jagdeo JR et al. Transcranial red and near infrared light transmission in a cadaveric model.PLoS One 2012;7:e47460, at a depth of 10 mm (the approximate thickness of a cadaveric skull and its intact soft tissue), the percentage of LED light penetration at a wavelength of 830 nm is 0.9% for the temporal lobe, 2.1% for the frontal lobe, and 11.7% for the occipital lobe. In addition, light absorption and attenuation caused by hair of various thicknesses, amounts, and colors can also be measured. That is, by taking into account the attenuation on the transmission path from the irradiation exit surface to the target brain tissue, the irradiation of the emitted near infrared light to the head of the subject satisfies the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level, and thus sufficient near infrared light per unit time power can be delivered to sufficient areas of the subject's head, and further sufficient near infrared light per unit time power can be delivered to sufficient areas of the brain tissue after attenuation on the transmission path, so as to achieve the optimized therapeutic effect of Alzheimer's disease and its associated diseases. The optimization of the therapeutic effect has also been confirmed through clinical experiments (described in detail below). The light therapy device of the present application has indeed demonstrated excellent "endurance" in inhibiting the course of AD. Specifically, not only did the subjects' cognitive level significantly improve during the period of light therapy, but their cognitive level was also maintained or improved during the period after the cessation of light therapy, and the subjects did not have any adverse reactions. The main mechanism of action of this discovery is estimated as follows, but the exact mechanism of action needs to be verified and confirmed through more experiments. AD is a whole-brain disease, and its pathological changes are not limited to a specific area of ​​the brain, but gradually spread from some areas to the whole brain, affecting multiple brain regions and neural networks. For example, the accumulation of Aβ in the brain follows a specific spatial trajectory, starting from the default mode network (DMN) area and gradually spreading to other low-order sensory-motor areas. In addition, single-cell transcriptomics studies have revealed cell type-specific changes in AD, that is, different cell populations have different population responses associated with AD, including but not limited to astrocytes, microglia, oligodendrocytes, neurons, vascular cells, peripheral glial cells, extracellular matrix, etc. Specifically, subpopulations of astrocytes have been found to be associated with cognitive decline, and they play a role in regulating the effects of tau protein on cognitive function. Different subpopulations of microglia are associated with the pathogenesis of AD, some subpopulations promote Aβ protein pathology, while others regulate the effects of Aβ protein on tau protein pathology. Specific responses of oligodendrocytes in AD are associated with disease progression, such as subpopulation-specific transcriptional changes. AD affects specific neuronal subpopulations, such as those in the hippocampus and cerebral cortex, which are closely associated with AD. Vascular cells include endothelial cells and pericytes, which play a role in vascular lesions in AD. Peripheral glial cells are associated with APOE expression and play a role in neurodegeneration in AD. Changes in the extracellular matrix are also associated with the progression of AD, affecting cell-cell interactions and signaling. As long as the irradiation of the emitted near-infrared light to the head of the subject meets the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level, near-infrared light of sufficient optical power can be delivered to sufficient areas of brain tissue per unit time. The irradiation surface area ratio of the local concentrated stimulation scheme can be as low as 30%, and the irradiation surface area ratio of the multi-zone balanced stimulation scheme can be as high as 65% or more. The irradiation power level that coordinates the irradiation surface area ratio within these ranges can achieve "modulation" and "excitation" of a sufficient proportion of cell populations. After the sufficient proportion of cell populations is "modulated" and "excited", not only does it itself undergo a change response that inhibits AD, but it can also transmit and diffuse the change response to other cell populations on the AD development space trajectory, thereby achieving a comprehensive AD inhibition effect throughout the brain. In this way, not only can the Aβ plaques accumulated in the neocortex be significantly reduced, the abnormal aggregation of tau protein in the neocortex, hippocampus and even the limbic cortex be significantly reduced, but also the AD-specific lesions of cell populations throughout the brain can be inhibited and reduced, thereby effectively inhibiting the course of AD and its associated diseases. Furthermore, in the period after phototherapy is stopped, a series of biochemical reactions caused by light radiation continue to trigger inhibitory effects, which not only maintains the inhibitory effect on AD to a certain extent, but can even continue to promote the inhibitory effect on AD without any degradation callback. In some embodiments, adaptation can be provided for local concentrated stimulation schemes and multi-zone balanced stimulation schemes. synergistic irradiation conditions. Specifically, the irradiated surface area ratio of the local concentrated stimulation scheme is smaller than that of the multi-zone balanced stimulation scheme, and the matched irradiation power level is also higher than that of the multi-zone balanced stimulation scheme. For example, as a local concentrated stimulation scheme, when the irradiated surface area ratio is 30% to 40%, the time-space average optical power density is required to be 117mW / cm 2 When the irradiated surface area ratio is between 40% and 65%, the spatiotemporal average optical power density irradiated to the subject's head is 110 mW / cm 2 Above. In this way, it is possible to break through the limitations of local cell populations, fully "modulate" and "stimulate" cell populations, and transmit and spread the change response that inhibits AD to other cell populations in a wider area on the spatial trajectory of AD development. Please note that the description of the % range in this application is defined as follows. "Between A% and B%" is intended to include percentages between A% and B%, but does not include A% or B%. "A% to B%" is intended to include percentages between A% and B%, and includes the two endpoint values ​​of A% and B%. The multi-zone balanced stimulation scheme requires an average synergistic dose of 2750W*% to 14100W*%, where the average synergistic dose is the product of the irradiated surface area ratio and the average total power, so the unit is watt*percentage. As the affected cell populations are more widely distributed, such as in multiple brain regions, multiple brain functional networks, etc., by delivering the above average synergistic dose, it is possible to appropriately "modulate" and "excite" the cell populations, and transmit and diffuse the change responses that inhibit AD to other cell populations in a wide area on the spatial trajectory of AD development. Please note that for various synergistic irradiation conditions of irradiated surface area ratios and irradiation power levels, the spatiotemporal average optical power density irradiated to the subject's head is 230mw / cm 2 To avoid thermal damage to tissue cells. The phototherapy device and head-mounted device 100 thereof according to the first embodiment of the present application are shown in FIG1( a). The supporting structure 101 is constructed as a head cap, and when the head cap is accommodated in the head cap, an appropriate gap is retained with the head cap, so that the head cap 103 of the subject can move. This loose and open head cap design does not feel restrained on the patient's head, and is especially friendly to the elderly who are emotionally agitated, anxious, resistant, or even afraid of confined or crowded spaces, and can significantly improve the treatment compliance of AD patients. The array 102 of near-infrared irradiation units can form a light panel and be assembled and fixed in the head cap. The light therapy device may also include a user terminal 19 configured to be interactively operated by a user. A computer storage medium may be configured in the user terminal 19, on which executable instructions are stored, and when the computer executable instructions are executed by the processor, various interactive steps with the user can be implemented. The storage medium may include a read-only memory (ROM), a flash memory, a random access memory (RAM), a dynamic random access memory (DRAM) such as a synchronous DRAM (SDRAM) or a Rambus DRAM, a static memory (e.g., a flash memory), a static random access memory), etc., on which computer executable instructions may be stored in any format. In some embodiments, the user terminal 19 is also used to receive a user's confirmation operation for the proposed infrared light therapy plan; after receiving the confirmation operation, irradiation is performed according to the confirmed infrared light therapy plan. Specifically, the controller (not shown) for controlling the irradiation may be located on the user terminal 19, or on the head-mounted device 100, or on a host different from the user terminal 19 and the head-mounted device 100. The controller may be implemented by various processors, and may be a processing device including one or more general processing devices, such as a microprocessor, a central processing unit (CPU), a graphics processing unit (GPU), etc., or may be one or more special processing devices, such as an application-specific integrated circuit (ASIC), a field programmable gate array (FPGA), a digital signal processor (DSP), a system on a chip (SoC), etc. Preferably, most of the calculations and processing are concentrated on the user terminal 19 to reduce the calculation load and software and hardware costs of the head-mounted device. The head-mounted device 100 is suspended on the bracket 20 via an elastic member 21, and the bracket 20 adopts a three-section free pivot structure to facilitate flexible adjustment of the position of the head-mounted device 100. In some embodiments, the light therapy device also carries a refrigerator 23 to introduce cold air into the light therapy device to implement sufficient and comfortable cooling around the subject's head 103, for example, stabilizing the temperature at about 43 degrees Celsius, or even about 41 degrees Celsius. FIG1(b) shows an exemplary structure of such a loose-fitting headgear 100. As shown in FIG1(b), the headgear 100 is implemented as a head cap, which includes an outer shell 1, a middle shell 2, and an inner shell 3 arranged in sequence from the outside to the inside. A light board accommodating cavity 4 with a plurality of light boards 5 (corresponding to the array 102 of near-infrared irradiation units in FIG1(a)) is formed between the outer shell 1 and the middle shell 2, and a cold air cavity 6 is formed between the middle shell 2 and the inner shell 3. The inner shell 3 is inwardly facing the inner shell 3. Enclosed to form a containing space. Among them, a plurality of air holes 7 are provided on the inner shell 3, so that the cold air passing through the cold air cavity 6 can enter the containing space from the air holes 7, and air holes 7 can be opened in the first area of ​​the inner shell 3 close to the top of the head and the second area below the first area. The second area is layered with a plurality of air hole units from top to bottom, wherein the arrangement of the upper air hole units and the lower air hole units is different, so as to cool down various areas of the patient's head and improve the synchronization and balance of cooling. During the light therapy of the patient, the whole head feels a more balanced temperature distribution and higher comfort. It can be seen that the inner shell 3 is the shell layer closest to the patient's head when the patient wears it, and a cold air cavity 6 is formed between the middle shell 2 and the inner shell 3, and the inner shell 3 and the middle shell 2 are configured to be light-transmissive. In this way, the near-infrared light (for example, a wavelength of 800-850nm) emitted by the lamp panel 5 can pass through the light-transmissive middle shell 2 and inner shell 3 in turn into the accommodating space, and irradiate the patient's head with a sufficient dose. In some embodiments, the inner shell 3 includes a first area close to the top of the head and a second area below the first area. Air holes 7 may be provided in the first area and the second area. As shown in FIG1(b), a cold air inlet 8 communicating with the cold air cavity 6 is provided on the middle shell 2, and a circle of air holes may be provided at least on the outer edge of the first area, and a cavity may be reserved for the top of the head for setting a protective pad. After the cold air enters the cold air cavity 6 through the cold air inlet 8, it passes through the air holes 7 and then blows toward the patient's head to ensure that the patient's head periphery and the top of the head can get a better cooling experience. In addition, the above structure enables the cold air to flow from the top of the patient's head to the bottom, which is beneficial to improving the heat exchange efficiency and temperature balance in the accommodation space. In this embodiment, the cold air inlet 8 of the cold air cavity 6 is arranged in the first area, and is closer to the rear of the inner shell 3 than the front of the inner shell 3, wherein the front of the inner shell 3 is the direction of the forehead corresponding to the head cap, and the rear of the inner shell 3 is the direction of the back of the head cap. In this way, the forehead area will not be overcooled, and the back of the head, which absorbs more light energy due to its large hair volume and produces more heat, can also feel the enhanced cooling effect, thereby improving the patient's comfort during phototherapy. This is just an example. In some embodiments, the cold air inlet 8 is kept close to the end of the front of the inner shell 3 (i.e., the edge position of the front of the inner shell 3) and the end of the back of the inner shell 3 (i.e., the edge position of the back of the inner shell 3) to avoid the problem of untimely and uneven regional cooling caused by the large difference in distance. In some embodiments, in order to more evenly transmit cold air to the accommodation space, the head cap may include a plurality of cold air inlets 8, and the plurality of cold air inlets 8 are distributed at different positions of the inner shell. The position setting of the cold air inlet 8 can be adjusted accordingly according to the specific head cap structure and the layout of the light therapy lamp panel. In some embodiments, the second region is layered from top to bottom with a plurality of air vent units, the upper air vent unit 701 and the lower air vent unit 703 are arranged in different ways, and the upper air vent unit 701 and the middle air vent unit 702 are arranged in the same way. For example, the number of air vents in a single lower air vent unit 703 is less than the number of air vents in a single upper air vent unit 701 or the middle air vent unit 702. For another example, air vents 7 having a relatively small air vent arrangement density compared to the upper air vent unit 701 are provided between adjacent upper air vent units 701. Such an arrangement enables the upper air vent unit 701 and the middle air vent unit 702 to release more cold air compared to the lower air vent unit 703. In some embodiments, the upper layer air permeable hole unit 701 and the middle layer air permeable hole unit 702 may both be composed of air permeable holes 7 uniformly distributed in an inner circle and air permeable holes 7 uniformly distributed in an outer circle. For example, the inner circle may have 6 air permeable holes 7 uniformly distributed and the outer circle may have 6 air permeable holes 7 uniformly distributed, while the lower layer air permeable hole unit 703 may only be composed of one circle of air permeable holes 7 uniformly distributed, for example, only 6 air permeable holes 7 uniformly distributed. The refrigerator 23 shown in FIG1(a), together with the cold air inlet 8, the cold air cavity 6, the air vent 7, the connection between the accommodating space and the external environment in FIG1(b), form a cooling mechanism. By means of the cooling mechanism, when the time-averaged total irradiation power irradiated to the subject's head 103 reaches 27.5-120W and the single continuous irradiation time reaches 30 minutes, the temperature of the air in the space adjacent to but not in contact with the subject's head 103 does not exceed 41°C, that is, the temperature of the surrounding air in which the subject's head 103 is immersed does not exceed 41°C. In some embodiments, the vent hole 7 is at least arranged at the corresponding position where the light board 5 is arranged. During the light treatment of the patient, the light board 5 irradiates the corresponding position of the patient's skin. Due to the high intensity of the light, It is easier to generate heat accumulation, and the air vent 7 is at least opened at the position of the inner shell 3 corresponding to the lamp board 5, which can prevent the lamp board 5 from irradiating the patient's skin and generating excessive heat accumulation. In some embodiments, the density of the air holes 7 at the corresponding positions of the light board 5 is greater than the density of the air holes 7 at the positions not corresponding to the light board 5, thereby further balancing the temperature at the corresponding positions of the light board 5 and other positions, enhancing the air permeability of the accommodation space, and improving the air heat exchange rate in the accommodation space. As an example, the loose-fitting headgear 100 shown in FIG1( b ) is particularly suitable for implementing a multi-zone balanced stimulation scheme. Of course, by flexibly controlling the light panel 5 , the loose-fitting headgear 100 can also implement a local concentrated stimulation scheme as needed. Fig. 2(a) shows a schematic diagram of a light therapy device according to a second embodiment of the present application. As shown in Fig. 2(a), the light therapy device includes a head mounted device 100 and a portable control terminal 104 which are in communication connection. The supporting mechanism 101 adopts a hollow frame that is pressed against the subject's head 103. The array 102 of near-infrared irradiation units forms discrete irradiation modules that are fixedly mounted on the hollow frame. Under the action of the hollow frame, the irradiation modules are tightly attached to the forehead, top of the skull, above the ears, etc. of the subject's head so as to emit near-infrared light to these parts. As an example, the control terminal 104 may be provided with operation buttons, such as but not limited to a start button, a pause button, and an off button, so that the operator can control the light therapy process by pressing the buttons. The control terminal 104 may also be provided with a display to present the operation information of the light therapy process to the operator, such as but not limited to the light control intensity and the remaining time of this treatment. Specifically, for example, the light therapy device of the structure shown in FIG2(a) is particularly suitable for implementing a localized concentrated stimulation scheme, and / or for treating the early stages of AD (e.g., MCI, mild dementia) and for preventive medical intervention for AD. Furthermore, the light therapy device of the structure shown in FIG2(a) has good portability, and the subject can conveniently use it at home or during travel, thereby ensuring the frequency and continuity of light therapy. FIG2(b) shows a schematic diagram of a light therapy device according to a third embodiment of the present application. The control and processing terminals thereof can refer to the other previous embodiments and are not shown here for the sake of simplicity. Different from the head-mounted device 100 shown in FIG1(b) and FIG2(a), the supporting mechanism 101 forms a significantly wider accommodation space in an arch or umbrella shape and is further away from the subject's head 103. In addition, the supporting mechanism 101 is rigidly mounted on a support or wall, for example, and the array 102 of near-infrared irradiation units forms discrete irradiation modules mounted on the inner wall of the supporting mechanism 101. In some embodiments, the coordinated irradiation condition of the irradiated surface area ratio and the irradiated power level can characterize the correlation between the irradiated surface area ratio and the spatiotemporal average light power density, such as the coordinated irradiation condition adopted by the local concentrated stimulation scheme when the irradiated surface area ratio is between 30% and 40% or between 40% and 65% as mentioned above; or characterize the product of the average total power irradiated to the head of the object and the total irradiated surface area ratio, such as the coordinated irradiation condition adopted by the multi-zone balanced stimulation scheme when the irradiated surface area ratio is above 65% as mentioned above. In other embodiments, the coordinated irradiation condition of the irradiated surface area ratio and the irradiated power level can be defined differently as needed, such as the integral of the power irradiated to each partition of the head of the object with respect to the irradiated surface area ratio of each partition, or the distribution of the power irradiated to each partition of the head of the object and the product of the irradiated surface area ratio of each partition, and so on. By refining the coordinated irradiation conditions for partition distribution, when the irradiation dose deviation in each brain area is large, it is possible to more effectively identify the situation where the corresponding light power or light power density of the partition is too low, ensuring that there are no blind spots in the "modulation" and "excitation" of the cell population. In some embodiments, the subject head may include a head of a patient, or a reference head model of a patient population. The specific structural parameters of the subject head mainly include head width, head length, head circumference, head sagittal arc, intertragus arc, morphological face length and head height, as shown in FIG3(a) to FIG3(f). In order to facilitate the implementation of the irradiation plan, the reference skull of the subject's head is divided into the front upper part 401a, the top part 401b, the left side 401c, the right side 401d, and the back 401e. The specific division scheme can be adjusted according to actual needs. For example, the division method shown in Figures 4(a) to 4(e) can be adopted. Specifically, the division is based on the 10-10 International Standard Lead System. The 10-10 International Standard Lead System is an electrode placement standard for electroencephalogram (EEG) recordings that provides an accurate and consistent way to mark and position electrodes on the head. In other words, the 10-10 system can be applied directly on the subject's head without transcranial placement. This system is an expansion of the earlier 10-20 system, which was proposed by the International Electroencephalography Society to standardize electrode locations in EEG recordings. In the 10-10 system, the location of the electrodes is based on the anatomical landmarks of the head, including the nasion, inion, and pre-auricular points. Through these landmarks, the front-back and left-right midline of the head can be determined, and the electrodes can be placed according to the 10% ratio. The naming convention of the 10-10 system is based on the 10-20 system, but provides a more dense electrode placement, especially in the base and front of the temporal lobe and the frontal lobe, targeting locations that are often overlooked in the 10-20 system. In addition, the 10-10 system also introduces some new electrodes to allow for more precise location division of brain region junctions, such as FC, which represents the electrode between the frontocentral region, FT, which represents the electrode between the frontotemporal region, CP, which represents the electrode between the central parietal region, and PO, which represents the electrode between the parietal occipital region. The electrode placement of the 10-10 system can effectively eliminate the influence of differences in the shape and size of individual heads, so that the same electrode position can basically accurately locate the same brain region node of different individuals; its denser electrode positions, especially those for the temporal lobe and frontal lobe, can obtain a more detailed division of the anterior upper skull 401a, top skull 401b, left skull 401c, right skull 401d and posterior skull 401e on the surface of the skull (outside the skull, scalp and hair), and accordingly achieve a more detailed division of each brain region (frontal lobe, parietal lobe, temporal lobe) under the skull and dura mater. In some embodiments, the front upper part of the skull 401a, the top of the skull 401b, the left side of the skull 401c, the right side of the skull 401d, and the back of the skull 401e can be defined based on their boundary lines. Referring to Figures 4 (a)-4 (e), the front upper part of the skull 401a is in the first area 402a surrounded by the first boundary line 400a and the total boundary line 400. According to the 10-10 standard lead system, the first boundary line 400a passes through the following electrode positions in sequence: between F7 and FT7, between F5 and FC5, between FC3 and C3, between FC1 and C1, between FCZ and CZ, between FC2 and C2, between FC4 and C4, between F6 and FC6, and between F8 and FT8. Please note that the small protrusions at each electrode position in Figures 4 (a)-4 (f) are only for the purpose of presenting the electrode positions more clearly in this application, and such small protrusions may not be provided in practice. For example, the small protrusions may not be provided on the surface of the reference head mold, which will not be described in detail here. The top of the skull 401b is within the second area 402b surrounded by the second boundary line 400b. According to the 10-10 standard lead system, the second boundary line 400b passes through the following electrode positions in sequence: between FC3 and C3, between FC1 and C1, between FCZ and CZ, between FC2 and C2, between FC4 and C4, between C6 and C4, between CP6 and CP4, between P6 and P4, between PO4 and P4, between PO4 and P2, between POZ and P2, between POZ and PZ, between POZ and P1, between PO3 and P1, between PO3 and P3, between P5 and P3, between CP5 and CP3, and between C5 and C3. The left side of the skull 401c is within a third region 402c surrounded by the third boundary line 400c and the total boundary line 400. According to the 10-10 standard lead system, the third boundary line 400c passes through the following electrode positions in sequence: between FT7 and F7, between FC5 and F5, between FC5 and FC3, between C5 and C3, between CP5 and CP3, between P5 and P3, between P5 and PO5, and between P7 and PO7. The right side of the skull 401d is within a fourth region 402d surrounded by the fourth boundary line 400d and the total boundary line 400. According to the 10-10 standard lead system, the fourth boundary line 400d passes through the following electrode positions in sequence: between FT8 and F8, between FC6 and F6, between FC6 and FC4, between C6 and C4, between CP6 and CP4, between P6 and P4, between P6 and PO6, and between P8 and PO8. The posterior skull 401e is within the fifth region 402e surrounded by the fifth boundary line 400e and the total boundary line 400. According to the 10-10 standard lead system, the fifth boundary line 400e passes through the following electrode positions in sequence: between P7 and PO7, between P5 and PO5, between P3 and PO3, between P1 and POZ, between PZ and POZ, between P2 and POZ, between P4 and PO4, between P6 and PO6, and between P8 and PO8. The so-called passing between electrode positions A and B in this application is intended to indicate an intermediate point on the line passing through electrode positions A and B. For example, the intermediate point can be the midpoint of the line, or it can be other points on the line. For example, at a point where the ratio of the distance between electrode positions A and B is 1:2. In some embodiments, for the same boundary line, such as the fifth boundary line 400e, the points passing between paired electrode positions may be at different ratios on the line, so that the boundary line formed by sequential connection is smooth. In some embodiments, the front upper part of the skull 401a, the top of the skull 401b, the left side of the skull 401c, the right side of the skull 401d, and the back of the skull 401e can also be defined based on the electrode positions they contain. Referring to Figures 4 (a)-4 (e), the front upper part of the skull 401a forms an area including electrode positions FP2, FPZ, FP1, AF3, AF4, AF7, AF8, AFZ, FZ, F1, F2, F3, F4, F5, F6, F7, F8, FC1, FC2, FC3, FC4, and FCZ. The top of the skull 401b forms an area including electrode positions CZ, C1, C2, C3, C4, CPZ, CP1, CP2, CP3, CP4, PZ, P1, P2, P3, and P4. The left side of the skull 401c forms an area including electrode positions FT7, FC5, T7, C5, TP7, CP5, P7, and P5, and the right side of the skull 401d forms an area including electrode positions FT8, FC6, T8, C6, TP8, CP6, P8, and P6. The back of the skull 401e forms an area including electrode positions PO7, PO5, PO3, POZ, PO4, P06, PO8, O1, OZ, and O2. As an example, in Figure 4 (a)-Figure 4 (e), the front upper part 401a of the skull, the top part 401b of the skull, the left side 401c of the skull, the right side 401d of the skull, and the back part 401e of the skull are connected to each other, without holes, and occupy the entire surface area of ​​the reference skull part 401 of the subject's head, but this is only an example. In some embodiments, the front upper part 401a of the skull, the top part 401b of the skull, the left side 401c of the skull, the right side 401d of the skull, and the back part 401e of the skull occupy more than 70% of the surface area of ​​the first area 402a, the second area 402b, the third area 402c, the fourth area 402d, and the fifth area 402e divided by their corresponding boundary lines, that is, the occupancy ratio is as low as 70%. Full irradiation of 70% of the surface area of ​​each area, through the optical diffusion effect of the subcranial brain tissue and the conduction between the brain area nodes, achieves a comprehensive AD inhibition effect within the whole brain. The above division is only used as an example. The front upper part 401a, the top part 401b, the left side 401c, the right side 401d, and the back part 401e can be adjusted and divided as needed, but preferably, each part mainly corresponds to the frontal lobe, the parietal lobe, the left temporal lobe, the right temporal lobe, and the occipital lobe. For example, each part of the front upper part 401a, the top part 401b, the left side 401c, the right side 401d, and the back part 401e can be divided into multiple island-shaped sub-areas around each group of electrode sites as shown in Figure 5 (a). For example, each part can also be divided into a whole block of connected state-shaped areas, in which small holes are opened, and some small holes can be opened around the electrode sites. More preferably, the front upper part 401a of the skull is distributed across the frontal lobe, the frontal lobe and the frontal lobe-central area, as shown in Figure 5 (c). Further, the top of the skull 401b is distributed across the central area, between the central area and the parietal lobe, and the parietal lobe, the left side of the skull 401c and the right side of the skull 401d are distributed across the frontal lobe-temporal lobe, the temporal lobe, and the temporal lobe-parietal lobe, and the back of the skull 401e is distributed across the parietal lobe-occipital lobe and the occipital lobe. More preferably, the left side of the skull 401c and the right side of the skull 401d are distributed across the lower part between the frontal lobe-central area, between the frontal lobe-temporal lobe, the temporal lobe, the lower part of the central area, the lower parietal lobe, between the temporal lobe-parietal lobe, and the lower part between the central area-parietal lobe. Through such a distribution, each part contains the connection sites between each brain area, and when irradiating by part, the connection sites between each brain area are fully irradiated, so that the transmission path of the "modulation" and "excitation" response of the cell group is smoother. In some embodiments, in the process of manufacturing a phototherapy device, a reference head model of a treatment population can be used to simulate, simulate or test the attenuation and transmission of near-infrared light. Specifically, a reference head model with representative dimensions can be selected based on the treatment population. For example, the concentrated age group of AD patients is over 60 years old. For the treatment population in this age group, the parameters of the reference head model can be: head width is 140-166mm, head length is 170-196mm, head circumference is 525-583mm, morphological surface length is 104-130mm, head sagittal arc is 304-372mm, intertragus arc is 320-375mm, and head height is 206-253mm. Specifically, the parameter range of the reference head model falls within the intersection of the distribution range of the parameter values ​​of P1, P5, P10, P50, P90, P95 and P99 of females in this age group and the parameter values ​​of P1, P10, P50, P90, P95 and P99 of males in this age group. Therefore, it is well representative for both males and females in this age group. In some embodiments, the parameters of the reference head model can be refined as follows: head width is 152 mm, head length is 184 mm, head circumference is 536.7 mm, morphological surface length is 109.3 mm, head sagittal arc is 355.6 mm, intertragus arc is 324.1 mm, and head height is 206 mm. At least part of the refined parameters are determined based on the P50 parameter values ​​of women in this age group and the P50 parameter values ​​of men in this age group. For example, the head width and head length here are the averages of two corresponding P50 parameter values. The P50 parameter values ​​of women in this age group are as follows: head width is 149 mm, head length is 180 mm, head circumference is 548 mm, morphological surface length is 111 mm, head sagittal arc is 335 mm, intertragus arc is 342 mm, and head height is 228 mm. The P50 parameter values ​​for males in this age group are as follows: head width is 155 mm, head length is 188 mm, head circumference is 565 mm, morphological length is 121 mm, head sagittal arc is 343 mm, intertragus arc is 351 mm, and head height is 231 mm. It can be seen that the parameters of the reference head model have a good fit with the P50 parameters of females and males in this age group, and are therefore more representative. Further, the cephalo-facial index of the parameter is 82%, which is also consistent with the cephalo-facial index range of the dominant head type (Brachycephaly) in Chinese (even East Asian populations). Therefore, the parameters of the reference head model are particularly well representative in Chinese and East Asian populations. In some embodiments, for populations with other cephalo-facial indices, such as but not limited to major human populations in Europe, South Asia, and Africa, each parameter can also be adaptively adjusted to have good representativeness. The electrode positions of the 10-10 international standard lead system can be measured and marked on the reference head model. In some embodiments, by adopting the above division of the upper front part 401a of the skull, the top of the skull 401b, the left side of the skull 401c, the right side of the skull 401d, and the back of the skull 401e, simulation, simulation or testing can be performed according to the details of the intended local concentrated stimulation scheme or the multi-zone balanced stimulation scheme. In some embodiments, the results of the simulation or simulation can be used to verify whether the designed light therapy device can meet the required coordinated irradiation conditions under the action of the intended implementation plan. The structure of the light therapy device, especially the three-dimensional spatial arrangement of the light board, can be adjusted accordingly. After the verification is completed, a prototype of the designed light therapy device can be manufactured, and the prototype can be used to irradiate the reference head model for testing and verification. It can be understood that if the actual test results on the reference head model are good, given that the size of the reference head model is well representative of the size of the individual heads of the treatment population, the results of the subsequent light therapy test of the treatment population are highly consistent. Such a manufacturing process can take into account both manufacturing costs and treatment effects. Specifically, in some embodiments, the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level can be defined as follows: When the irradiation surface area ratio of the emitted near-infrared light to the head of the subject is 30% to 40%, the spatiotemporal average optical power density irradiated to the head of the subject is 117 mW / cm 2 Above and 230mW / cm 2 For example, at this irradiated surface area ratio, the value of the spatiotemporal average optical power density irradiated to the subject's head (in mW / cm 2 ) can be any point in the numerical range of 117 to 230, starting from 117 and distributed at an interval of 0.5-1. When the irradiated surface area ratio is between 40% and 65%, the spatiotemporal average optical power density irradiated to the subject's head is above 110 mW / cm2 and 230 mW / cm 2 For example, at this irradiated surface area ratio, the value of the spatiotemporal average optical power density irradiated to the subject's head (in mW / cm 2 ) can be any point in the numerical range of 110 to 230, starting from 110 and distributed at an interval of 0.5-1. When the irradiated surface area ratio is above 65%, the average synergistic dose irradiated to the subject's head is 2750W*% to 14100W*%, wherein the average synergistic dose is the product of the irradiated surface area ratio and the average total power, and the spatiotemporal average optical power density irradiated to the subject's head is 230mw / cm 2 For example, at this irradiated surface area ratio, the value of the average synergistic dose (in W*%) irradiated to the subject's head can be any point in the numerical range of 2750 to 14100, starting from 2750 and distributed at intervals of 10. However, in the actual manufacturing and verification process, there is no need to exhaustively enumerate every ratio of the above irradiated surface area ratios. A portion of them can also be selected to simulate, simulate or test whether the phototherapy equipment meets the corresponding coordinated irradiation conditions. By using the flexible combination of the above front upper part 401a, top part 401b, left side 401c, right side 401d and back part 401e, multiple representative irradiated surface area ratios can be obtained, so as to facilitate The simulation and verification of local concentrated stimulation scheme or multi-zone balanced stimulation scheme can be realized efficiently. As an example, as shown in FIG. 4(a) to FIG. 4(e), the first region 402a, the second region 402b, the third region 402c, the fourth region 402d and the fifth region 402e are respectively used as the front upper part 401a of the skull, the top part 401b of the skull, the left side part 401c of the skull, the right side part 401d of the skull and the back part 401e of the skull, then the ratio of the surface area of ​​each part to the surface area of ​​the reference skull part is shown in Table 1: Table 1 Surface area ratios of the upper front part of the skull, the top of the skull, the left side of the skull, the right side of the skull and the back of the skull relative to the reference skull That is, the emitted near-infrared light can irradiate any of the following areas of the subject's head: the front upper part of the skull; the front upper part of the skull and the top of the skull, as shown in FIG6(a); the front upper part of the skull, the left side of the skull and the right side of the skull, as shown in FIG6(b); the front upper part of the skull, the left side of the skull, the right side of the skull and the top of the skull, as shown in FIG6(c); the front upper part of the skull, the left side of the skull, the right side of the skull, the top of the skull and the back of the skull, as shown in FIG6(d). As an example, when only the front upper part of the subject's head is irradiated, the irradiated surface area ratio is 35.7% (satisfying 30% to 40%), and the spatiotemporal average optical power density irradiated to the subject's head is 117 mW / cm 2 Above and 230mW / cm 2 When only the front upper part and top of the head of the subject are irradiated, the irradiated surface area ratio is 59.21% (satisfying between 40% and 65%), or when only the front upper part, left side of the head and right side of the head of the subject are irradiated, the irradiated surface area ratio is 64.03% (satisfying between 40% and 65%), and the spatiotemporal average optical power density irradiated to the subject's head is 110mW / cm 2 Above and 230mW / cm 2Below. When irradiating the front upper part of the skull, the left side of the skull, the right side of the skull and the top of the skull of the subject, the irradiation surface area ratio is 87.54%, and the average synergistic dose is 2750W*% to 10800W*% of the reference skull surface area. When irradiating the front upper part of the skull, the left side of the skull, the right side of the skull, the top of the skull and the back of the skull of the subject, the irradiation surface area ratio is 100%, and the average synergistic dose is 2750W*% to 14100W*% of the reference skull surface area. That is to say, after the reference head mold of the subject's head is manufactured, if each part adopts the above division method, as long as the targeted irradiation is carried out according to the corresponding combination method of the above parts, it is convenient to apply multiple irradiation surface area ratios of 30% to 100%, such as 35.7%, 59.21%, 64.03%, 87.54% or 100%. In some embodiments, any irradiated surface area ratio in the range of 30% to 100% can be flexibly achieved by irradiating only part of each part or a combination of several parts, for example, any percentage value starting from 30% and distributed at intervals of 5%. Accordingly, the phototherapy device can be adjusted, and the irradiation parameters under the corresponding combination mode can be detected to check whether the spatiotemporal average light power density or the average synergistic dose meets the intended synergistic irradiation conditions. If so, the calibration of the irradiation parameters of the phototherapy device under this combination mode is completed. Furthermore, after leaving the factory, if the user uses a customized combination of each part, the corresponding calibration can also be performed as above to ensure that the customized combination of each part can meet the required synergistic irradiation conditions and ensure the therapeutic effect on AD. In some embodiments, the time-space average optical power density corresponding to the first proportion of the emitted near-infrared light irradiating the reference skull surface area of ​​the object's head is greater than the time-space average optical power density corresponding to the second proportion of the emitted near-infrared light irradiating the reference skull surface area of ​​the object's head, wherein the first proportion is smaller than the second proportion. The first proportion and the second proportion may be selected from any one of the following. For example, the first proportion and the second proportion may both be between 30% and 40%. For example, the first proportion may be between 30% and 40%, and the second proportion may be between 40% and 65%. For example, the first proportion may be between 40% and 65%, and the second proportion may be above 65%. For another example, the first proportion and the second proportion may both be above 65%. In some embodiments, the expected time-space average optical power density corresponding to various irradiated surface area proportions may be analyzed by simulating and modeling the light irradiation process of the phototherapy device relative to the object's head. Specifically, In the present invention, the energy attenuation of the near-infrared light of the corresponding wavelength in various parts of the scalp, various parts of the skull, cerebrospinal fluid, dura mater, arachnoid mater and pia mater can be taken into account, and the surface area ratio and the spatiotemporal average optical power density delivered to the target brain area, such as the prefrontal lobe, can be used as the target to perform simulation, so as to determine the irradiation area and the spatiotemporal average optical power density of the reference skull surface irradiated to the subject's head. When performing the simulation, the irradiation surface area ratio can be adjusted by adjusting the irradiation area irradiated to the reference skull surface of the subject's head, and the spatiotemporal average optical power density irradiated to the reference skull surface of the subject's head can be adjusted accordingly according to the spatiotemporal average optical power density relationship between the first ratio and the second ratio, so as to obtain a specific coordinated irradiation scheme for the reference skull surface of the subject's head, so as to calibrate, inspect and actually operate the light therapy device in the future. As described above, the inventors creatively discovered that: for the efficacy of phototherapy for AD, the time-averaged irradiation power level and the ratio of irradiated surface area delivered to brain tissue are important factors of synergy. Accordingly, the synergistic irradiation conditions that need to be met for irradiating near-infrared light to the head of the object can be characterized in various ways as an important factor of the time-averaged irradiation power level. For example, the time-averaged irradiation power level can be characterized as the spatiotemporal average light power density, or the total power, or as a composite parameter after calculation with the irradiated surface area (such as product, integral, etc.). In some embodiments, the average total irradiation power of the emitted near-infrared light irradiated to the head of the object is 23-140W, or 29-120W, or 31-100W. In some embodiments, the corresponding average total irradiation power can also be adapted according to the course of AD. For AD patients whose target areas are not clear or are discretely distributed, a multi-zone balanced stimulation scheme is preferred. For example, the front upper part of the skull, the left side of the skull, the right side of the skull and the top of the skull can be irradiated, or the front upper part of the skull, the left side of the skull, the right side of the skull, the top of the skull and the back of the skull can be irradiated. The division of each part can refer to the description in other embodiments, but is not limited to this. Among them, the spatiotemporal average light power density irradiated to the front upper part of the skull is 50-120mW / cm 2 The spatial and temporal average optical power density irradiated to the top of the skull is 60-120 mW / cm 2 The time-space average optical power density irradiated to the left and right sides of the skull is 32-85 mW / cm 2 In some embodiments, the spatiotemporal average optical power density irradiated to the front upper part of the skull, the top of the skull, the left side of the skull, or the right side of the skull can be 4-10 mW / cm from the lower limit in the above corresponding range. 2 Any value obtained for the interval. In some embodiments, if the upper front skull 401a, the left skull 401c, the right skull 401d, the top skull 401b and the back skull 401e all contain corresponding electrode positions as shown in Figures 4(a)-4(e), respectively, the requirements for the spatiotemporal average optical power density can be refined to the electrode site clusters, thereby accurately reflecting the fluctuations in the temporal average optical power density of the electrode sites, especially at the boundaries of each part. In some embodiments, the time-averaged optical power density irradiated to the electrode positions Fp1, Fpz, Fp2, AF3, AFz, AF4, F5, F3, F1, Fz, F2, F4, F6, FC1, FC2, FC3, FC4, FC5, FC6, C1, C2, C3, Cz, C4, C5, C6, CP1, CP2, CPz, CP3, CP4, P1, P2, Pz is 50-90 mW / cm 2 The time-averaged optical power density at the electrode positions FCz, P3, P4, TP7, FT7, T7, FT8, T8, POz, P6, TP8, CP6, P5, CP5, F7, F8, AF7, and AF8 is 25-65 mW / cm 2 . In some embodiments, when irradiating the front upper part of the skull, the left side of the skull, the right side of the skull, the top of the skull, and the back of the skull, the time-averaged optical power density irradiated to the electrode positions P8, PO8, O1, O2, Oz, P7, and PO7 is 1 mW / cm 2 Up to 30mW / cm 2 , that is, it can fluctuate within this range. For a multi-zone balanced stimulation scheme, a head-mounted device 100 with a loose head cap design as shown in FIG1(b) may be used. In some embodiments, adjacent near-infrared irradiation units (such as LED lamp beads) are spaced apart by a preset interval, and each near-infrared irradiation unit has a preset emission angle, so that when the subject's head is in place in the accommodation space: near-infrared light is emitted everywhere on the peripheral irradiation surface corresponding to the reference skull portion of the subject's head. The phototherapy device and the head-mounted device 100 are further described below in conjunction with FIGS. 7-9, wherein the peripheral irradiation surface is implemented as the irradiation surface of the transparent inner shell 3, and the surface area of ​​the peripheral irradiation surface is 1200-1700cm 2 . In some embodiments, a plurality of light boards 5 are arranged on the middle shell 2 through a light board fixing shell 9. The light board fixing shell cover 9 is arranged on the side of the middle shell 2 close to the outer shell 1. As shown in FIG8 , in some embodiments, a light board fixing shell 9 is arranged in the light board accommodating cavity 4, and the light board fixing shell 9 is covered on the side of the middle shell 2 close to the outer shell 1. A plurality of light boards 5 are arranged in layers from top to bottom along the light board fixing shell 9, and the spacing between the two light boards 5 on the upper layer is greater than the spacing between the two adjacent light boards 5 on the lower layer, so as to ensure that different brain regions of the corresponding patients can achieve effective light therapy effects. In some embodiments, the light boards corresponding to the top of the patient's head are arranged with a lower density, and more dense light boards can be arranged at other head positions except the top of the patient's head, but this is only an example. Specifically, the inventor creatively discovered that, especially in the head-mounted device 100 shown in FIGS. 7 to 9 , when the subject's head is in place, a space of at least several centimeters or even nearly 10 centimeters is reserved on the top of the head to reduce the subject's sense of oppression during phototherapy, but the near-infrared light emitted by multiple lamp beads can overlap on the surface of the subject's head after propagating through the interval, and the near-infrared light beams emitted by each lamp panel can also overlap on the surface of the subject's head after propagating through the interval, so that the light power density on the surface can be maintained at, for example, 80-120 mW / cm 2 level. Please note that the multi-layer circumferential distribution of multiple light panels 5 is only an example of an array of near-infrared irradiation units. The array of near-infrared irradiation units may also use LEDs, laser diodes, or optical fibers that transmit near-infrared light from the outside, etc., which are not described here. In some embodiments, the array of near-infrared irradiation units may be specifically constructed to emit near-infrared light with a duty cycle of 30%-70%, a wavelength of 650-1100nm, and a frequency falling within the frequency range of Alpha waves, the frequency range of Gamma waves, or the neighborhood of these two. Among them, a single near-infrared irradiation device used to constitute the near-infrared irradiation unit may be an LED, and its average optical power may be above 90mW. In other embodiments of the present application, a plurality of light panels 5 may be directly disposed on the middle shell 2 . In some embodiments, as shown in FIG. 8 , six layers of light boards 5 are spaced apart on the light board fixing shell 9 , and the light boards 5 include at least one of the following configurations. Method 1: In the first layer of light boards 10 that are closest to the top of the head cap, there is a first gap between two adjacent light boards, and the length of the narrowest position a of the first gap ranges from 23mm to 26mm, and the length of the widest position b of the first gap ranges from 57mm to 60mm. Furthermore, the length of the narrowest position a of the first gap ranges from 23.5mm to 25.5mm, and the length of the widest position b of the first gap ranges from 57.5mm to 59.5mm. Preferably, the length of the narrowest position a of the first gap is about 24mm, and the length of the widest position b of the first gap is about 59mm. Please note that the reference to a certain numerical value in this application is intended to take measurement errors into account. Mode 2: In the second layer of light boards 11 adjacent to the first layer of light boards 10, there is a second gap between two adjacent light boards, and the length of the second gap at the narrowest position ranges from 15mm to 18mm, and the length of the second gap at the widest position ranges from 41mm to 44mm. Further, the length of the second gap at the narrowest position ranges from 16mm to 17.5mm, and the length of the second gap at the widest position ranges from 41mm to 43mm. Preferably, the length of the second gap at the narrowest position is about 16.7mm, and the length of the first gap at the widest position is about 42.5mm. Mode three: In the third layer of light boards 12 located below the second layer of light boards 11, there is a third gap between two adjacent light boards, and the length of the third gap at the narrowest position ranges from 13mm to 16mm, and the length of the third gap at the widest position ranges from 24mm to 27mm. Further, the length of the third gap at the narrowest position ranges from 13.5mm to 15.5mm, and the length of the third gap at the widest position ranges from 24mm to 26mm. Preferably, the length of the third gap at the narrowest position is about 14.2mm, and the length of the third gap at the widest position is about 25.3mm. Method 4: In the fourth layer of light boards 13, the fifth layer of light boards 14 and the sixth layer of light boards 15, which are located below the third layer of light boards 12 and are arranged from top to bottom, there is a fourth gap between two adjacent light boards of the fourth layer of light boards 13, and the length of the fourth gap at the narrowest position ranges from 12mm to 15mm, and the length of the fourth gap at the widest position ranges from 19mm to 22mm. Furthermore, the length of the fourth gap at the narrowest position ranges from 13.5mm to 14.5mm, and the length of the fourth gap at the widest position ranges from 19.5mm to 21.5mm. Preferably, the length of the fourth gap at the narrowest position is about 14mm, and the length of the fourth gap at the widest position is about 20.5mm. Mode 5: There is a fifth gap between two adjacent light boards of the fifth layer of light boards 14, the length of the fifth gap at the narrowest position ranges from 12mm to 15mm, and the length of the fifth gap at the widest position ranges from 16mm to 19mm. Further, the length of the fifth gap at the narrowest position ranges from 13mm to 14.5mm, and the length of the fifth gap at the widest position ranges from 16mm to 19mm. The length ranges from 16.5 mm to 18.5 mm. Preferably, the length of the narrowest position of the fifth gap is about 13.8 mm, and the length of the widest position of the fifth gap is about 18 mm. Mode 6: There is a sixth gap between two adjacent lamp boards of the sixth layer of lamp boards 15, and the length of the sixth gap at the narrowest position ranges from 11mm to 14mm, and the length of the sixth gap at the widest position ranges from 15mm to 18mm. Further, the length of the sixth gap at the narrowest position ranges from 12mm to 14mm, and the length of the sixth gap at the widest position ranges from 15mm to 17mm. Preferably, the length of the sixth gap at the narrowest position is about 13mm, and the length of the sixth gap at the widest position is about 16.2mm. The arrangement of the above structure can make the overall temperature inside the head cap reach dynamic balance under the premise of irradiation by the lamp board 5 to achieve the light therapy effect. The spacing arrangement of the above lamp boards 5 and the setting between adjacent layers of the lamp boards 5 avoid the concentrated heat dissipation of the lamp boards 5, prevent the local temperature inside the head cap from being too high, and save energy. In an optional embodiment, as shown in FIG8 , the gap between two adjacent lamp boards 5 in each layer of lamp boards 5 has a narrowest position and a widest position, respectively, and the width of the gap between two adjacent lamp boards 5 on the upper layer is greater than the width of the gap between two adjacent lamp boards 5 on the lower layer. In this way, under the premise of ensuring that the lamp boards 5 are irradiated to achieve the phototherapy effect, the situation in which the local temperature in the phototherapy head cap is too high due to the dense arrangement of the lamp boards 5 is significantly reduced. Among them, due to the structural design of the head cap of the phototherapy equipment, the accommodating space forms a trend of gradually increasing the inner diameter from top to bottom, so the arrangement spacing of the first layer of lamp boards 10 and the second layer of lamp boards 11 is enlarged, and under the premise of ensuring the uniformity of the light power density, the heat emitted by the lamp boards 5 is prevented from accumulating in the head cap, which is convenient for cooling. In order to achieve the uniformity of the light power density of the entire accommodating space, the optimal average light power of the first layer of lamp boards 10 and the second layer of lamp boards 11 can be 75mw to 125mw, preferably 90-100mw. As shown in Fig. 8, in some embodiments, the vertical spacing between the first layer of light boards 10 and the second layer of light boards 11 is 19 mm to 25 mm, preferably 19.5 mm to 24.5 mm. The vertical spacing between the second layer of light boards 11 and the third layer of light boards 12 is 14 mm to 21 mm, preferably 15 mm to 20 mm. As shown in Fig. 8, in some embodiments, the vertical spacing between the other two adjacent layers of light panels is 13 mm to 19 mm, preferably 14 mm to 18 mm. The vertical spacing between the two adjacent layers of light panels can not only satisfy the requirement of irradiating the entire brain area, but also prevent the heat emitted by the light panels 5 from accumulating in the accommodation space. Therefore, the arrangement of the light panel 5 can illuminate the entire area of ​​the patient's head, will not affect the normal progress of light therapy, and can also improve the comfort of the treatment process, where the patient's head area includes the temporal lobe, occipital lobe, frontal lobe and parietal lobe. 9 , the light board 5 is connected to the light board fixing frame 17, and the light board 5 is fixed to the light board fixing housing 9 through the light board fixing frame 17. In some embodiments, the spacing between adjacent light board fixing frames 17 in each layer of light board fixing frames 17 is similar to or the same as the spacing between the corresponding adjacent light boards 5. Returning to Figure 7 and in conjunction with Figure 1(b), in some embodiments, the head cap is provided with an annular connecting portion 18, and the bottoms of the outer shell 1 and the middle shell 2 are respectively connected to the connecting portion 18. The connecting portion 18 is provided with a plurality of vents 16 that communicate with the light board accommodating cavity 4, and the area of ​​each vent 16 located at the rear end of the head cap is larger than the area of ​​each vent 16 located at the front end of the head cap. Furthermore, the vent 16 may be in the shape of an elongated strip. This can increase the amount of wind entering the rear end of the head cap, so as to improve the cooling effect of the light board accommodating cavity 4 and balance the cooling effect at the back of the head and forehead of the head cap. It can also reduce the heat transfer from the light board accommodating cavity 4 to the cold air cavity 6, thereby facilitating improving the cooling effect of the accommodating space. In some embodiments, an exhaust port is provided on the top of the head cap, and the exhaust port is communicated with the light board accommodating cavity 4 for extracting hot air from the light board accommodating cavity 4. In some embodiments, a total of 80 lamp boards 5 are distributed inside the head cap, the size of the near-infrared light outlet of each lamp board 5 is 28mm×28mm, with a tolerance of ±0.2mm, and the lamp beads are arranged in a 3×3 array. We have used the light therapy device of this structure to conduct a series of clinical experiments. As an example, the central wavelength of the near-infrared light emitted by the array of near-infrared irradiation units is 810nm, the duty cycle is 50%, and the frequency is 10Hz, but it should be noted that this is only an example. In some embodiments, near-infrared light may be emitted with a duty cycle of 30%-70%, a wavelength of 650-1100nm, and a frequency falling within the frequency range of Alpha waves, the frequency range of Gamma waves, or a neighborhood of the two, which will not be elaborated here. In some embodiments, the array of near-infrared irradiation units is specifically configured to irradiate at least 8260-42250 joules of energy to the subject's head within a continuous irradiation time of 5 minutes as a unit dose. The 8260 joules of energy irradiation within 5 minutes is equivalent to continuous irradiation of the skull with a time-averaged irradiation power of 27.5 W, assuming that the surface area of ​​the skull is 612.35 cm 2 To calculate, the time-space average optical power density is 45mW / cm 2 ; 42250 joules of energy irradiation in 5 minutes is equivalent to continuous irradiation of the skull with a time-averaged irradiation power of 140W, with a surface area of ​​612.35cm 2 The time-space average optical power density is 230 mW / cm 2The inventor found in clinical experiments that it is difficult for some AD patients in the moderate and severe dementia stages to continue irradiation for more than 10 minutes to half an hour without interruption. Some AD patients have severe cognitive impairment and are uncooperative. Some AD patients also frequently have abnormal limb movements, such as muscle stiffness and flexion, muscle atrophy and weakness, and apraxia. Taking 5 minutes as the unit dose means that every 5 minutes of irradiation has a certain effect of inhibiting AD. For example, the energy dose required to be irradiated to the head of the subject in a single period of 1 hour, such as 3 unit doses, at least 24800 joules-126800 joules of energy, can be executed separately as separate or continuous effective unit doses, so that the cumulative dose delivered in a single period can achieve a comparable AD inhibition effect as the cumulative dose delivered in a single period continuously for 15 minutes. In the actual treatment process, even if the AD patient's own reasons or operational failures cause interruptions, the operator only needs to ensure that the accumulated irradiation time in a single period meets the requirements, and there is no need to restart the light therapy equipment, nor to reset the current irradiation dose, and there is no need to rigidly interrupt the irradiation. Specifically, if the subject has a high degree of cooperation and the treatment is also smooth, it can be directly irradiated for 15 minutes. If the subject's cooperation is low or the treatment is not smooth, the subject must go to the bathroom after 6 minutes, for example, and the treatment can be temporarily interrupted, and the irradiation can be continued when he returns. The interruption time can be flexibly adjusted according to the needs of the subject, as long as the irradiation duration is achieved within 1 hour. This significantly reduces the difficulty of light therapy for AD patients with severe cognitive impairment or movement abnormalities that lead to lack of cooperation, as well as groups with varying degrees of AD severity (such as nursing home populations across age groups), and even for caregivers who lack experience in caring for AD patients. In some embodiments, the array of the near-infrared irradiation unit is specifically configured to irradiate at least 24800 joules-1014050 joules of energy to the head of the subject in a single day as a single-day cumulative dose. It can be seen that the single-day cumulative dose can have a span of nearly 40 times, with a lower limit of 15 minutes of cumulative irradiation at a time-averaged irradiation power of 27.5W, and an upper limit of 2 hours of irradiation at a time-averaged irradiation power of 140W. The inventors found that using the light therapy device of the present application, the single-day cumulative dose can be adjusted in a large span according to the adaptability of the object. Specifically, if the subject has a high degree of cooperation with light therapy and the individual response is good, the array of the near-infrared irradiation unit is specifically configured to implement a single-period cumulative dose by continuously irradiating for more than 30 minutes in a single period of 1 hour, and up to 4 times in a single day to provide an accelerated single-day cumulative dose. The accelerated single-day cumulative dose is equivalent to the amount of the lower limit of the single-day cumulative dose for several days. In the case where the subject needs to interrupt treatment for a few days due to specific circumstances, the accelerated single-day cumulative dose can be performed first, which increases the flexibility and convenience of light therapy. In addition, although the mechanism of action is not yet clear, the improvement in cognitive performance after accelerated single-day cumulative doses to individual volunteers is even better than the effect of the same cumulative doses administered over several days. In some embodiments, the weekly cumulative dose to the subject's head can be as low as 24,800 joules, and the irradiation time can be as little as 15 minutes. In some embodiments, the array of near-infrared irradiation units is specifically configured to provide at least 124,000 joules (27.5 W-15 minutes-5 times) to 7,100,000 (230 mw / cm 2 -2 hours per day -7 days) joules of energy are irradiated to the subject's head as a weekly cumulative dose. Specifically, the single-period cumulative dose can be divided into time periods and implemented 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times or 8 times on each day of the irradiation each week. Specifically, the array of the near-infrared irradiation units is specifically configured to implement more than 8 times of the weekly cumulative dose within 8 weeks, preferably more than 16 times of the weekly cumulative dose within 16 weeks, as the cumulative dose for the course of treatment. In some embodiments, the interruption time between two treatment courses does not exceed half of the duration of the treatment course, so as to minimize the deterioration of AD pathological conditions caused by interrupted treatment. The applicant conducted a clinical experiment on the test group (i.e., the treatment group) using the phototherapy device as shown in Figures 1(a) and 1(b). The spatiotemporal average light power density of the phototherapy device at various parts of the reference head model of the subject's head and the temporal average light power density at the center position of the lamp panel corresponding to the irradiated surface of the inner shell 3 are shown in Table 2. Table 2 Time-space average optical power density of the phototherapy device at various parts of the reference head model The applicant conducted a clinical experiment on the test group (ie, the treatment group) using the light therapy device with the operating parameters in Table 3. Table 3 Operating parameters of light therapy equipment The phototherapy device in this clinical experiment, when the subject's head is in place in the accommodation space formed by the supporting mechanism, can emit near-infrared light that can cover the upper front part of the skull, the top of the skull, the left side of the skull, the right side of the skull and the back of the skull of the subject, and the irradiated surface area ratio is greater than 65%, meeting the synergistic irradiation conditions of the irradiated surface area ratio and the irradiation power level. As shown in Tables 2 and 3, the average synergistic dose irradiated to the subject's head is about 3200W*% to 4800W*%, and the spatiotemporal average optical power density irradiated to the subject's head is 230mw / cm 2 the following. The inclusion criteria for this clinical trial are as follows: (1) meeting the core criteria for probable Alzheimer's disease (AD) defined by the National Institute on Aging-Alzheimer's Association (NIA-AA); (2) brain MRI The results of the examination (within 6 months) support the possible diagnosis of AD; (3) Aged 50-85 years old, regardless of gender; (4) MMSE score <26 points, and able to cooperate in completing the scale assessment; (5) The patient is not taking medication. If taking psychiatric or cognitive improvement drugs, the dosage must be stable for at least 12 weeks before the experiment and remain unchanged during treatment. Exclusion criteria: (1) the presence of contraindications to MRI, such as metal implants or claustrophobia; (2) other types of dementia or other psychiatric or neurological diseases, such as depression or Parkinson's disease; (3) a history of stroke or epilepsy; (4) photosensitivity to sunlight or visible light, or increased skin sensitivity in the treatment area; (5) severe visual or hearing impairment; (6) a history of alcohol or drug addiction; (7) any other condition that is not suitable for participation in this study. According to the inclusion and exclusion criteria, a total of 27 patients were enrolled, 13 in the experimental group and 14 in the control group. The treatment group received whole-head near-infrared light stimulation: wavelength 810nm, frequency 10Hz, each participant received a 30-minute treatment once a day, 6 days a week, for 4 months. The regimen of the sham treatment group (control group) was exactly the same as that of the near-infrared light treatment group, but a sham treatment head cap was used. The light emitted by the sham treatment device is visually identical to the near-infrared treatment device, and during the treatment process, a sound similar to that of the near-infrared treatment device and a warm feeling on the scalp are produced, but the light power is very weak and is basically absorbed by the tissue, and the effect of stimulating brain tissue cannot be achieved, as shown in Figure 10. The scale assessment was conducted at the 2nd and 4th month of the treatment period, and at 2 and 4 months (6th and 8th month) after the end of treatment, as shown in Figure 10. The assessors, subjects, and their caregivers were blinded to the treatment allocation throughout the study until the end of the study. And the treatment allocation was not discussed by the relevant personnel throughout the study. The subjects all believed that they were receiving real near-infrared treatment. Finally, a total of 18 patients (9 in the treatment group and 9 in the control group) completed 4 months of treatment and 4 months of assessment. Among them, 1 patient only completed the MMSE scale assessment in the scale assessment, and did not complete the ADAS-cog scale. The ADAS-Cog scale consists of 12 items, covering memory, orientation, language, application, attention, etc. It can assess the severity of AD cognitive symptoms and treatment changes, and is often used for the efficacy evaluation of mild to moderate AD (usually an improvement of 4 points is used as a clinical criterion for drug efficacy). The MMSE scale is the most widely used cognitive screening scale at home and abroad, covering orientation, memory, attention, calculation, language ability and visual-spatial ability. Studies on MMSE have found that in professional institutions such as memory clinics or in community hospitals, the sensitivity and specificity of MMSE in distinguishing normal elderly people from dementia are both above 80%, which has good value in screening dementia. In order to explore the sustainability of the efficacy of near-infrared light on AD patients, a follow-up visit was conducted on the subjects after the treatment. A total of 14 subjects completed the 8th month follow-up (that is, 4 months after the end of treatment, 8 in the treatment group and 6 in the control group). Referring to Figures 11(a) and 11(b), it can be seen that the ADAS-cog scale scores of the subjects in the treatment group decreased by an average of 1.11 points from the baseline after 2 months of light therapy, and continued to decrease at a greater slope after 4 months of treatment, with an average decrease of 6.04 points from the baseline, and the statistical significance within the group was p = 0.034 < 0.05, which was significantly better than the scores of the control group. Within 2 months after the end of treatment, the ADAS-cog scale scores of the treatment group fluctuated less, and remained at an average decrease of 5.59 points from the baseline 2 months after the end of treatment, and the statistical significance within the group was p = 0.009 < 0.05. In the follow-up visit 2 months after the end of treatment, the ADAS-cog scale scores of the treatment group even began to continue to decline, and decreased by an average of 8.25 points from the baseline 4 months after the end of treatment, and the statistical difference within the group was p = 0.008 < 0.05. Judging from the ADAS-cog scale scores, the phototherapy device of the present application has achieved beneficial effects that have never appeared in papers and related literature on other existing phototherapy devices: within the 4 months of phototherapy, the ADAS-cog scale scores decreased at a larger slope after the second month compared with the first two months; two follow-up visits every 2 months after the end of phototherapy found that the biochemical reaction caused by the irradiation energy of the near-infrared light delivered to the subject's head continued to trigger an inhibitory effect after the end of phototherapy, not only maintaining the inhibitory effect on AD to a certain extent, but even continuously promoting the inhibitory effect on AD, and there was no deterioration callback of the ADAS-cog scale score. As shown in Figure 12(a) and Figure 12(b), the MMSE scores of the subjects in the treatment group increased by an average of 0.67 points from the baseline after 2 months of light therapy. During the following 2 months of light therapy, the MMSE scores continued to increase at a larger slope. By the 4th month of light therapy, the scores had increased by an average of 2.78 points from the baseline. The score was significantly better than that of the control group, with a statistical significance of P = 0.025 < 0.05 within the group. From the perspective of both the ADAS-cog scale score and the MMSE scale score in the first 2 months and the last 2 months of phototherapy, similar improvement effects were shown: the last 2 months continued to improve at a larger slope. Further, similar to the continued improvement of the ADAS-cog scale score after the end of phototherapy, 2 months after the end of phototherapy, although phototherapy was stopped, the MMSE scale score continued to rise, and even retained an upward slope comparable to that during phototherapy. By 2 months after the end, the average increase from baseline was 3.89 points, with a statistical significance of p = 0.004 < 0.05 within the group. 4 months after the end of phototherapy, the MMSE scale score of the treatment group was still comparable to the MMSE scale score obtained 4 months after phototherapy, and no deterioration callback occurred. In other words, judging from the MMSE scale scores, the biochemical reaction caused by the irradiation energy of near-infrared light delivered to the subject's head continued to trigger an inhibitory effect after the end of phototherapy, not only maintaining the inhibitory effect on AD to a certain extent, but even continuing to promote the inhibitory effect on AD, and there was no deterioration callback in the ADAS-cog scale scores. Combined with the results of follow-up visits during and after the light therapy, the optimized "light charging" and continuous benefit process of the light therapy device of the present application mentioned above were also confirmed: the "light charging capacity" of the subject's brain was larger, the "light charging depth" was deeper, and the "light charging speed" was faster. The scale scores improved significantly in the first 2 months and the last 2 months of the light therapy, and occurred at a stable slope without stagnation; the subsequent "endurance" ability and continuous benefit were better, and the effect of 2 months of light therapy was maintained for at least 2 months after the end of light therapy, and even for 4 months after the end of light therapy. Moreover, the biochemical reaction caused by "light charging" continued to trigger the inhibitory effect after the end of light therapy, and continued to promote the inhibitory effect on AD without deterioration callback. Moreover, after 4 months of near-infrared light therapy, the resting-state functional magnetic resonance imaging results of the subjects in the treatment group showed that ALFF in multiple brain regions of the frontal lobe, occipital lobe, and temporal lobe was enhanced (P<0.05), indicating that the excitability and spontaneous activity of the subjects' neurons were enhanced, providing neuroimaging evidence for the improvement of corresponding cognitive functions. At the same time, no adverse events related to the test device were observed in this trial. Although phototherapy lasted for 4 months in this clinical trial, phototherapy showed the characteristics of deep regulation and sustained and even cumulative benefits. If it is used for a longer period of time, such as 6 months, 8 months, 10 months,... more than 1 year, or even year-round, the benefits are expected to continue to increase, reflecting a more significant disease modification effect. In addition, although exemplary embodiments have been described herein, the scope includes any and all embodiments based on the present disclosure with equivalent elements, modifications, omissions, combinations (e.g., various embodiments intersecting schemes), adaptations or changes. The elements in the claims will be interpreted broadly based on the language adopted in the claims, and are not limited to the examples described in this specification or during the implementation of this application, and the examples will be interpreted as non-exclusive. Therefore, this specification and examples are intended to be considered as examples only, and the true scope and spirit are indicated by the following claims and the full scope of their equivalents. The above description is intended to be illustrative rather than restrictive. For example, the above examples (or one or more of them) can be used in combination with each other. For example, a person of ordinary skill in the art can use other embodiments when reading the above description. In addition, in the above-mentioned specific embodiments, various features can be grouped together to simplify the present disclosure. This should not be interpreted as an intention that a disclosed feature that is not required to be protected is necessary for any claim. On the contrary, the subject matter of the present disclosure may be less than all the features of a specific disclosed embodiment. Thus, the following claims are incorporated into the specific embodiments as examples or embodiments, wherein each claim is independently used as a separate embodiment, and it is considered that these embodiments can be combined with each other in various combinations or arrangements. The scope of the present disclosure should be determined with reference to the attached claims and the full scope of equivalent forms granted by these claims. The above embodiments are only exemplary embodiments of the present disclosure and are not intended to limit the present disclosure. The protection scope of the present disclosure is defined by the claims. Those skilled in the art may make various modifications or equivalent substitutions to the present disclosure within the essence and protection scope of the present disclosure, and such modifications or equivalent substitutions shall also be deemed to fall within the protection scope of the present disclosure.

Claims

1. A light therapy device for treating Alzheimer's disease and its associated diseases, characterized in that: include: A carrying mechanism, the carrying mechanism being configured to form a receiving space for the subject's head and to carry an array of near-infrared irradiation units; as well as The array of near-infrared irradiation units is constructed as follows: near-infrared light is emitted into a receiving space, and when the subject's head is in place in the receiving space, the irradiation of the subject's head with the emitted near-infrared light satisfies the coordinated irradiation conditions of the irradiation surface area ratio and the irradiation power level, the irradiation surface area ratio is the ratio of the irradiation surface area to the reference skull surface area, the reference skull surface area is the outer surface area of ​​the surface of the subject's head within the total boundary line, the total boundary line runs from the brow point of the subject's head along the brow bone through the preauricular points on both sides, and goes back around the occipital protuberance and merges with the electrode positions O1, OZ and O2 of the 10-10 international standard lead system, the irradiation surface area ratio can be as low as 30%, or as high as 65% or more.

2. The light therapy device according to claim 1, characterized in that The coordinated irradiation conditions of the irradiated surface area ratio and the irradiated power level include at least one of the following: When the ratio of the irradiated surface area of ​​the emitted near-infrared light to the head of the subject is 30% to 40%, the spatiotemporal average optical power density irradiated to the head of the subject is 117 mW / cm 2 Above and 230mW / cm 2 the following; The spatiotemporal average optical power density irradiated to the subject’s head was 110 mW / cm2 when the irradiated surface area ratio was between 40% and 65%. 2 Above and 230mW / cm 2 the following; When the irradiated surface area ratio is above 65%, the average synergistic dose irradiated to the subject's head is 2750W*% to 14100W*%, wherein the average synergistic dose is the product of the percentage of the irradiated surface area ratio and the average total power, and the spatiotemporal average optical power density irradiated to the subject's head is 230mw / cm 2 the following.

3. The light therapy device according to claim 1, characterized in that The coordinated irradiation conditions of the irradiated surface area ratio and the irradiated power level are characterized by at least one of the following: The correlation between the irradiated surface area ratio and the spatiotemporal average optical power density; the product of the average total power irradiated to the subject's head and the percentage of the total irradiated surface area ratio; or The integral of the power irradiated to each subarea of ​​the subject's head with respect to the irradiated surface area ratio of each subarea.

4. The light therapy device according to any one of claims 1 to 3, characterized in that The coordinated irradiation conditions of the irradiated surface area ratio and the irradiated power level specifically include any of the following: When only the upper front part of the subject's head is irradiated, the spatiotemporal average optical power density irradiated to the subject's head is 117 mW / cm 2 Above and 230mW / cm 2 the following; When only the front upper part and the top of the skull of the subject are irradiated, or only the front upper part, the left side of the skull and the right side of the skull are irradiated, the spatiotemporal average optical power density irradiated to the subject's head is 110 mW / cm 2 Above and 230mW / cm 2 the following; When irradiating the front upper part, left side of the skull, right side of the skull and top of the skull of the subject, the average synergistic dose is 2750W*% to 10800W*%; When irradiating the front upper part, left side of the skull, right side of the skull, top of the skull and back of the skull of the subject, the average synergistic dose was 2750 W*% to 14100 W*%.

5. The light therapy device according to claim 1, characterized in that The average optical power density corresponding to a first proportion of the emitted near-infrared light irradiating the reference skull surface of the object's head is greater than the average optical power density corresponding to a second proportion of the emitted near-infrared light irradiating the reference skull surface of the object's head, wherein the first proportion is smaller than the second proportion.

6. The light therapy device according to claim 5, characterized in that The first ratio and the second ratio are selected from any one of the following: The first ratio and the second ratio are both 30% to 40%; The first ratio is between 30% and 40%, and the second ratio is between 40% and 65%; The first ratio and the second ratio are both between 40% and 65%; The first ratio is between 40% and 65%, and the second ratio is above 65%; The first ratio and the second ratio are both above 65%.

7. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The average total irradiation power of the emitted near-infrared light irradiated to the subject's head is 23-140W, or 29-120W, or 31-100W.

8. The light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The subject's head includes a head of a treatment subject, or a reference head model of a treatment subject population, wherein the emitted near-infrared light irradiates any of the following areas of the subject's head: anterior upper skull; posterior upper skull and skull top; posterior upper skull, left skull and right skull; posterior upper skull, left skull, right skull and skull top; posterior upper skull, left skull, right skull, skull top and posterior skull, The parameters of the reference head model of the patient population are any of the following: Head width is 140-166mm, head length is 170-196mm, head circumference is 525-583mm, face length is 104-130mm, head sagittal arc is 304-372mm, intertragus arc is 320-375mm, head height is 206-253mm; or The head width is 152mm, the head length is 184mm, the head circumference is 536.7mm, the facial length is 109.3mm, the head sagittal arc is 355.6mm, the intertragus arc is 324.1mm, and the head height is 206mm.

9. The light therapy device according to claim 8, characterized in that According to the 10-10 standard lead system, The upper front part of the skull forms an area including electrode positions FP2, FPZ, FP1, AF3, AF4, AF7, AF8, AFZ, FZ, F1, F2, F3, F4, F5, F6, F7, F8, FC1, FC2, FC3, FC4, and FCZ, The top of the skull forms an area including electrode positions CZ, C1, C2, C3, C4, CPZ, CP1, CP2, CP3, CP4, PZ, P1, P2, P3, P4, The left side of the skull forms an area including electrode positions FT7, FC5, T7, C5, TP7, CP5, P7, and P5, and the right side of the skull forms an area including electrode positions FT8, FC6, T8, C6, TP8, CP6, P8, and P6, The posterior skull forms an area including electrode locations PO7, PO5, PO3, POZ, PO4, P06, PO8, O1, OZ and O2.

10. The light therapy device according to claim 8, characterized in that The front upper part of the skull is within a first area surrounded by the first boundary line and the total boundary line, and according to the 10-10 standard lead system, the first boundary line passes through the following electrode positions in sequence: between F7 and FT7, between F5 and FC5, between FC3 and C3, between FC1 and C1, between FCZ and CZ, between FC2 and C2, between FC4 and C4, between F6 and FC6, and between F8 and FT8; The second border line passes through the second area surrounded by the second border line at the top of the skull in the following electrode positions in sequence according to the 10-10 standard lead system: between FC3 and C3, between FC1 and C1, between FCZ and CZ, between FC2 and C2, between FC4 and C4, between C6 and C4, between CP6 and CP4, between P6 and P4, between PO4 and P4, between PO4 and P2, between POZ and P2, between POZ and PZ, between POZ and P1, between PO3 and P1, between PO3 and P3, between P5 and P3, between CP5 and CP3, and between C5 and C3; The left side of the skull is within a third area surrounded by the third boundary line and the total boundary line, and according to the 10-10 standard lead system, the third boundary line passes through the following electrode positions in sequence: between FT7 and F7, between FC5 and F5, between FC5 and FC3, between C5 and C3, between CP5 and CP3, between P5 and P3, between P5 and PO5, and between P7 and PO7; The right side of the skull is within a fourth area surrounded by a fourth boundary line and the total boundary line, and according to the 10-10 standard lead system, the fourth boundary line passes through the following electrode positions in sequence: between FT8 and F8, between FC6 and F6, between FC6 and FC4, between C6 and C4, between CP6 and CP4, between P6 and P4, between P6 and PO6, and between P8 and PO8; The posterior skull is within the fifth area surrounded by the fifth boundary line and the total boundary line. According to the 10-10 standard lead system, the fifth boundary line passes through the following electrode positions in sequence: between P7 and PO7, between P5 and PO5, between P3 and PO3, between P1 and POZ, between PZ and POZ, between P2 and POZ, between P4 and PO4, between P6 and PO6, and between P8 and PO8.

11. The light therapy device according to claim 10, characterized in that The surface area of ​​the upper front part of the skull is more than 70% of the surface area of ​​the first region, the surface area of ​​the top of the skull is more than 70% of the surface area of ​​the second region, the surface area of ​​the left side of the skull is more than 70% of the surface area of ​​the third region, the surface area of ​​the right side of the skull is more than 70% of the surface area of ​​the fourth region, and the surface area of ​​the back of the skull is more than 70% of the surface area of ​​the fifth region.

12. The light therapy device according to claim 8, characterized in that In the case of irradiation to the upper front part of the skull, the left side of the skull, the right side of the skull and the top of the skull, or to the upper front part of the skull, the left side of the skull, the right side of the skull, the top of the skull and the back of the skull, The spatiotemporal average optical power density irradiated to the upper front part of the skull is 50-120 mW / cm 2 The spatial and temporal average optical power density irradiated to the top of the skull is 60-120 mW / cm 2 The time-space average optical power density irradiated to the left and right sides of the skull is 32-85 mW / cm 2 .

13. The light therapy device according to claim 8, characterized in that When at least the front upper part of the skull, the left side of the skull, the right side of the skull and the top of the skull are irradiated, The time-averaged optical power density irradiated to the electrode positions Fp1, Fpz, Fp2, AF3, AFz, AF4, F5, F3, F1, Fz, F2, F4, F6, FC1, FC2, FC3, FC4, FC5, FC6, C1, C2, C3, Cz, C4, C5, C6, CP1, CP2, CPz, CP3, CP4, P1, P2, Pz is 50-90 mW / cm 2 , The time-averaged optical power density at the electrode positions FCz, P3, P4, TP7, FT7, T7, FT8, T8, POz, P6, TP8, CP6, P5, CP5, F7, F8, AF7, and AF8 is 25-65 mW / cm 2 .

14. The light therapy device according to claim 13, characterized in that When irradiating the front upper part of the skull, the left side of the skull, the right side of the skull, the top of the skull and the back of the skull, the time average light power density irradiating the electrode positions P8, PO8, O1, O2, Oz, P7, PO7 is 1mW / cm 2 Up to 30mW / cm 2 .

15. The light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The unit dose irradiated to the subject's head is: at least 8260-42250 joules of energy are irradiated to the subject's head within a continuous irradiation time of 5 minutes.

16. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The single-session cumulative dose irradiated to the subject's head is: irradiating at least 24,800 joules to 126,800 joules of energy to the subject's head in a single period of 1 hour in separate or continuous effective unit doses.

17. The light therapy device according to claim 16, characterized in that The cumulative dose in a single period can reach a cumulative irradiation time of more than 30 minutes in a single period of 1 hour.

18. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The single-day cumulative dose irradiated to the subject's head is: at least 24800 joules to 1014050 joules of energy are irradiated to the subject's head in separate single-period cumulative doses within a single day.

19. The light therapy device of claim 18, wherein: In case the single-session cumulative dose reaches a cumulative irradiation time of 30 minutes within a single session of 1 hour, it can be implemented up to 4 times to provide an accelerated single-day cumulative dose.

20. The light therapy device according to any one of claims 1 to 3, 5 and 6, characterized in that The weekly cumulative dose delivered to a subject's head can be as low as 24,800 joules, and the irradiation time can be as little as 15 minutes.

21. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterised in that The weekly cumulative dose irradiated to the subject's head is: at least 124,000 joules to 7,100,000 joules of energy are irradiated to the subject's head in separate single-period cumulative doses within a week, and the single-period cumulative dose can be implemented 1, 2, 3, 4, 5, 6, 7 or 8 times in separate periods on each day of the week when irradiation is implemented.

22. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterised in that The phototherapy device also includes a cooling mechanism, which is configured to ensure that the temperature of the air in the space adjacent to but not in contact with the subject's head does not exceed 41°C when the time-averaged total irradiation power irradiated to the subject's head reaches 27.5-120W and the single continuous irradiation duration reaches 30 minutes.

23. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterised in that There is a preset interval between adjacent near-infrared irradiation units, and each near-infrared irradiation unit has a preset emission angle, so that when the object's head is in place in the accommodating space: near-infrared light is emitted everywhere on the peripheral irradiation surface corresponding to the reference skull cover of the object's head.

24. The light therapy device according to claim 23, characterized in that The surface area of ​​the peripheral irradiated curved surface is 1200-1700 cm 2 .

25. A light therapy device according to any one of claims 1 to 3, 5 and 6, characterised in that The array of the near-infrared irradiation units is specifically constructed to emit near-infrared light with a duty cycle of 30%-70%, a wavelength of 650-1100nm, and a frequency falling within the frequency range of Alpha waves, the frequency range of Gamma waves, or the neighborhood of the two, wherein the time-averaged optical power of a single near-infrared irradiation device used to constitute the near-infrared irradiation unit is above 90mW.

Images